Expert Opinion on Biological Therapy最新文献_第6页

The chimera of reaching a universal consensus on platelet-rich plasma treatment for knee osteoarthritis: a review of recent consensus statements and expert opinion. 就富血小板血浆治疗膝骨关节炎达成普遍共识的 "锲机"：近期共识声明和专家意见综述。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1080/14712598.2024.2383865

Elizaveta Kon, Giuseppe Anzillotti, Pietro Conte, Luca Ruosi, Brian Cole, Jason Dragoo, Ken Zaslav, Rachel Frank, Laura De Girolamo, Bert Mandelbaum, Scott Rodeo, Maurilio Marcacci, Giuseppe Filardo, Berardo Di Matteo

{"title":"The chimera of reaching a universal consensus on platelet-rich plasma treatment for knee osteoarthritis: a review of recent consensus statements and expert opinion.","authors":"Elizaveta Kon, Giuseppe Anzillotti, Pietro Conte, Luca Ruosi, Brian Cole, Jason Dragoo, Ken Zaslav, Rachel Frank, Laura De Girolamo, Bert Mandelbaum, Scott Rodeo, Maurilio Marcacci, Giuseppe Filardo, Berardo Di Matteo","doi":"10.1080/14712598.2024.2383865","DOIUrl":"10.1080/14712598.2024.2383865","url":null,"abstract":"Introduction: Osteoarthritis (OA) is a prevalent cause of disability worldwide, affecting millions and posing significant socioeconomic burdens. Various conservative measures like hyaluronic acid (HA) and platelet-rich plasma (PRP) injections aim to manage OA symptoms and delay surgical interventions. Despite the increasing utilization of PRP, consensus on its efficacy remains elusive, reflecting the evolving landscape of OA management.Areas covered: This study reviews guidelines and recommendations on intra-articular PRP injections for OA globally, highlighting divergent perspectives among different medical societies. A comprehensive literature search identified 19 relevant guidelines, indicating a temporal and geographic evolution in attitudes toward PRP use. While some guidelines endorse PRP for mild-to-moderate OA, others express caution due to concerns about product standardization and clinical evidence heterogeneity.Expert opinion: The lack of universal consensus on PRP for OA underscores the complex interplay between clinical evidence, practice patterns, and evolving perspectives. Recent shifts toward endorsing PRP may reflect advancements in preparation techniques and personalized medicine approaches. However, challenges persist, including patient selection and product standardization. Efforts to develop consensus and refine PRP classification systems are essential for guiding clinical practice and advancing OA management.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"827-833"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting gut and intratumoral microbiota: a novel strategy to improve therapy resistance in cancer with a focus on urologic tumors. 针对肠道和肿瘤内微生物群：改善癌症耐药性的新策略，重点关注泌尿系统肿瘤。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-24 DOI: 10.1080/14712598.2024.2371543

Bingquan Wu, Chao Quan, Yunbo He, Juliet Matsika, Jinliang Huang, Bolong Liu, Jinbo Chen

{"title":"Targeting gut and intratumoral microbiota: a novel strategy to improve therapy resistance in cancer with a focus on urologic tumors.","authors":"Bingquan Wu, Chao Quan, Yunbo He, Juliet Matsika, Jinliang Huang, Bolong Liu, Jinbo Chen","doi":"10.1080/14712598.2024.2371543","DOIUrl":"10.1080/14712598.2024.2371543","url":null,"abstract":"Introduction: Growing attention has been drawn to urologic tumors due to their rising incidence and suboptimal clinical treatment outcomes. Cancer therapy resistance poses a significant challenge in clinical oncology, limiting the efficacy of conventional treatments and contributing to disease progression. Recent research has unveiled a complex interplay between the host microbiota and cancer cells, highlighting the role of the microbiota in modulating therapeutic responses.Areas covered: We used the PubMed and Web of Science search engines to identify key publications in the fields of tumor progression and urologic tumor treatment, specifically focusing on the role of the microbiota. In this review, we summarize the current literature on how microbiota influence the tumor microenvironment and anti-tumor immunity, as well as their impact on treatments for urinary system malignancies, highlighting promising future applications.Expert opinion: We explore how the composition and function of the gut microbiota influence the tumor microenvironment and immune response, ultimately impacting treatment outcomes. Additionally, we discuss emerging strategies targeting the microbiota to enhance therapeutic efficacy and overcome resistance. The application of antibiotics, fecal microbiota transplantation, and oncolytic bacteria has improved tumor treatment outcomes, which provides a novel insight into developing therapeutic strategies for urologic cancer.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"747-759"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review. 治疗瘘管化克罗恩病的药物疗法潜力：最新综述。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-24 DOI: 10.1080/14712598.2024.2383882

Mohammad Shehab, Davide De Marco, Peter L Lakatos, Talat Bessissow

{"title":"The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review.","authors":"Mohammad Shehab, Davide De Marco, Peter L Lakatos, Talat Bessissow","doi":"10.1080/14712598.2024.2383882","DOIUrl":"10.1080/14712598.2024.2383882","url":null,"abstract":"Introduction: Crohn's disease (CD) is a chronic, relapsing immune mediated disease, which is one of the two major types of inflammatory bowel disease (IBD). Fistulizing CD poses a significant clinical challenge for physicians. Effective management of CD requires a multidisciplinary approach, involving a gastroenterologist and a GI surgeon while tailoring treatment to each patient's unique risk factors, clinical representations, and preferences.Areas covered: This comprehensive review explores the intricacies of fistulizing CD including its manifestations, types, impact on quality of life, management strategies, and novel therapies under investigation.Expert opinion: Antibiotics are often used as first-line therapy to treat symptoms. Biologics that selectively target TNF-α, such infliximab (IFX), have shown high efficacy in randomized controlled trials. However, more than 50% of patients lose response to IFX, prompting them to explore alternative strategies. Current options include adalimumab and certolizumab pegol combination therapies, as well as small-molecule drugs targeting Janus kinases such as Upadacitinib. Furthermore, a promising treatment for complex fistulas is mesenchymal stem cells such as Darvadstrocel (Alofisel), an allogeneic stem cell-based therapy. However, surgical interventions are necessary for complex cases or intra-abdominal complications. Setons and LIFT procedures are the most common surgical options.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"733-746"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis. 优化类风湿性关节炎抗肿瘤坏死因子-α疗法的停药策略。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1080/14712598.2024.2384000

Aliki I Venetsanopoulou, Paraskevi V Voulgari, Alexandros A Drosos

{"title":"Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis.","authors":"Aliki I Venetsanopoulou, Paraskevi V Voulgari, Alexandros A Drosos","doi":"10.1080/14712598.2024.2384000","DOIUrl":"10.1080/14712598.2024.2384000","url":null,"abstract":"Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that significantly impacts patients' quality of life. While treatment options have expanded over the years, including the introduction of tumor necrosis factor-alpha (TNFα) inhibitors (TNFi), optimizing withdrawal strategies for these agents remains a challenge.Areas covered: This review examines the current evidence on TNFi withdrawal strategies in RA, focusing on factors influencing withdrawal decisions such as disease activity monitoring, treatment response, patient characteristics, and biomarkers. A comprehensive literature search was conducted, including randomized controlled trials, observational studies, and expert guidelines. The pathophysiology of RA, current pharmacological agents, and the treat-to-target strategy are discussed to provide a holistic understanding of RA management.Expert opinion: Withdrawal strategies could be suitable for certain patients, keeping in mind that several factors influence withdrawal decisions, including treatment response, disease activity and monitoring, and patient characteristics. The decision to withdraw TNFi must balance the benefits against the potential risks of disease flare and long-term treatment-related adverse effects. Combining DMARDs and TNFi early improves outcomes, supporting tapering strategies for cost-effectiveness and flare prevention. Future directions, including precision medicine approaches, patient-centered care models, and health economics analyses, are proposed to further optimize RA management and improve patient outcomes.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"815-825"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases. 将腺相关病毒载体用于神经系统疾病的基因治疗。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-31 DOI: 10.1080/14712598.2024.2386339

Shinichi Kumagai, Takeshi Nakajima, Shin-Ichi Muramatsu

{"title":"Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases.","authors":"Shinichi Kumagai, Takeshi Nakajima, Shin-Ichi Muramatsu","doi":"10.1080/14712598.2024.2386339","DOIUrl":"10.1080/14712598.2024.2386339","url":null,"abstract":"Introduction: In gene therapy with adeno-associated virus (AAV) vectors for diseases of the central nervous system, the vectors can be administered into blood vessels, cerebrospinal fluid space, or the brain parenchyma. When gene transfer to a large area of the brain is required, the first two methods are used, but for diseases in which local gene transfer is expected to be effective, vectors are administered directly into the brain parenchyma.Areas covered: Strategies for intraparenchymal vector delivery in gene therapy for Parkinson's disease, aromatic l-amino acid decarboxylase (AADC) deficiency, and epilepsy are reviewed.Expert opinion: Stereotactic intraparenchymal injection of AAV vectors allows precise gene delivery to the target site. Although more surgically invasive than intravascular or intrathecal administration, intraparenchymal vector delivery has the advantage of a lower vector dose, and preexisting neutralizing antibodies have little effect on the transduction efficacy. This approach improves motor function in AADC deficiency and led to regulatory approval of an AAV vector for the disease in the EU. Although further validation through clinical studies is needed, direct infusion of viral vectors into the brain parenchyma is expected to be a novel treatment for Parkinson's disease and drug-resistant epilepsy.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"773-785"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations. 用前沿疗法治疗轴性脊柱关节炎：进步与创新。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-27 DOI: 10.1080/14712598.2024.2389987

Giuseppe Lopalco, Andrea Cito, Vincenzo Venerito, Florenzo Iannone, Fabian Proft

{"title":"The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations.","authors":"Giuseppe Lopalco, Andrea Cito, Vincenzo Venerito, Florenzo Iannone, Fabian Proft","doi":"10.1080/14712598.2024.2389987","DOIUrl":"10.1080/14712598.2024.2389987","url":null,"abstract":"Introduction: Axial involvement in spondyloarthritis has significantly evolved from the original 1984 New York criteria for ankylosing spondylitis, leading to an improved understanding of axial spondyloarthritis (axSpA) as a disease continuum encompassing non- radiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA). A clear definition for early axSpA has been established, underscoring the need for early intervention with biological and targeted synthetic drugs to mitigate pain, reduce functional impairment, and prevent radiographic progression.Areas covered: This review explores therapeutic strategies in axSpA management, focusing on biological and targeted synthetic therapies and recent advancements. Biologics targeting TNFα or IL-17 and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) are primary treatment options. These therapies significantly impact clinical outcomes, radiographic progression, and patient-reported functional improvement.Expert opinion: AxSpA treatment has evolved significantly, offering various therapeutic options. Biological DMARDs, particularly TNFα inhibitors, have transformed treatment, significantly enhancing patient outcomes. However, challenges persist for patients unresponsive or intolerant to existing therapies. Emerging therapeutic targets promise to address these challenges. Comprehensive management strategies and personalized approaches, considering extra-articular manifestations and individual patient factors, are crucial for achieving optimal outcomes in axSpA management.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"835-853"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents. 易患结膜炎和男性性别会降低成人和青少年服用杜比鲁单抗的药物存活率。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-25 DOI: 10.1080/14712598.2024.2372367

Luca Mastorino, Irene Richiardi, Federica Gelato, Giovanni Cavaliere, Pietro Quaglino, Michela Ortoncelli, Simone Ribero

{"title":"Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents.","authors":"Luca Mastorino, Irene Richiardi, Federica Gelato, Giovanni Cavaliere, Pietro Quaglino, Michela Ortoncelli, Simone Ribero","doi":"10.1080/14712598.2024.2372367","DOIUrl":"10.1080/14712598.2024.2372367","url":null,"abstract":"Background: There are currently limited data on dupilumab drug survival (DS), especially on factors possibly associated with drug discontinuation.Materials and methods: The primary endpoint of this study is to evaluate the parameters that may determine drug discontinuation and the predictive factors associated with dupilumab DS. We considered as independent associated factors: childhood onset of disease, gender, age of onset of AD, age of initiation of dupilumab, previous use of cyclosporine, initial mean EASI, atopic family history, and predisposition to allergic conjunctivitis.Results: On 413 patients DS was 94.5% at 1 year, 89.5% at 2 years, and 83.7% at 3 years, and after a mean follow-up of 40.5 months (±1.6) 53 patients had discontinued the drug permanently (12.8%). Univariate analysis showed that the only factor associated with a reduction in drug survival was a predisposition to allergic conjunctivitis (p 0.009). At multivariate Cox regression, male sex (HR, 2.34; 95% CI, 1.14-4.78; p 0.02) and predisposition to allergic conjunctivitis (HR, 2.61; 95% CI, 1.37-5.00; p 0.004) were associated with lower DS of dupilumab.Conclusion: Male gender and predisposition to allergic conjunctivitis are negative predictors for maintenance of response to treatment with dupilumab and consequently associated with lower DS rates.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"863-868"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies. 展望治疗血液恶性肿瘤的 CD3、T 细胞吸引双特异性抗体。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-29 DOI: 10.1080/14712598.2024.2384086

Daniel R Reed, Lawrence G Lum

{"title":"Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies.","authors":"Daniel R Reed, Lawrence G Lum","doi":"10.1080/14712598.2024.2384086","DOIUrl":"10.1080/14712598.2024.2384086","url":null,"abstract":"Introduction: Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded in hematologic malignancies. Many have recently received Food Drug Administration and European Medicines Agency approvals in various stages of treatment for lymphomas, leukemias, and multiple myeloma.Areas covered: The purpose of this review is to provide an overview of bispecific antibody treatment including the mechanisms leading to effector T cells targeting tumor-associated antigens, the treatment indications, efficacies, toxicities, and challenges of the different constructs. A literature search was performed through access to PubMed and clinicaltrials.gov.Expert opinion: While there has been substantial success in the treatment of NHL, MM, and ALL, there are still hematologic malignancies such as AML where there has been limited progress. It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"761-772"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19. 开发针对 COVID-19 新病毒变异的单克隆抗体的考虑因素。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-06 DOI: 10.1080/14712598.2024.2388186

Arturo Casadevall, Scott McConnell, Daniele Focosi

{"title":"Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19.","authors":"Arturo Casadevall, Scott McConnell, Daniele Focosi","doi":"10.1080/14712598.2024.2388186","DOIUrl":"10.1080/14712598.2024.2388186","url":null,"abstract":"Introduction: Monoclonal antibody (mAb) therapies proved safe and effective in preventing progression of COVID-19 to hospitalization, but most were eventually defeated by continued viral evolution. mAb combinations and those mAbs that were deliberatively selected to target conserved regions of the SARS-CoV-2 spike protein proved more resilient to viral escape variants as evident by longer clinical useful lives.Areas covered: We searched PubMed for literature covering the need, development, and use of mAb therapies for COVID-19. As much of humanity now has immunity to SARS-CoV-2, the population at most risk is that of immunocompromised individuals. Hence, there continues to be a need for mAb therapies for immunocompromised patients. However, mAb use in this population carries the risk for selecting mAb-resistant variants, which could pose a public health concern if they disseminate to the general population.Expert opinion: Going forward, structural knowledge of the interactions of Spike with its cellular receptor has identified several regions that may be good targets for future mAb therapeutics. A focus on designing variant-resistant mAbs together with cocktails that target several epitopes and the use of other variant mitigating strategies such as the concomitant use of small molecule antivirals and polyclonal preparations could extend the clinical usefulness of future preparations.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"787-797"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center. 幼年特发性关节炎中依那西普疗效和安全性的真实数据：在一个中心进行的为期24个月的回顾性研究。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-06 DOI: 10.1080/14712598.2024.2388193

Ramazan Emre Yiğit, Kadir Ulu, Şengül Çağlayan, Betül Sözeri

{"title":"Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center.","authors":"Ramazan Emre Yiğit, Kadir Ulu, Şengül Çağlayan, Betül Sözeri","doi":"10.1080/14712598.2024.2388193","DOIUrl":"10.1080/14712598.2024.2388193","url":null,"abstract":"Objective: The aim of this study was to assess the efficacy and safety of etanercept (ETA) use in juvenile idiopathic arthritis (JIA).Methods: The 24-month data of patients with JIA on etanercept in a single center were evaluated retrospectively. Response to treatment was assessed according to 10-joint Juvenile Arthritis Disease Activity Score (JADAS10), and JIA-American College of Rheumatology (ACR) improvement criteria. Safety assessments were based on adverse event (AE) reports.Results: The study included 152 patients with JIA. The mean age at diagnosis of JIA was 8.5 ± 4.4 years, and treatment with ETA started at a mean age of 11.1 ± 4.4 years. The mean duration of ETA use was 16 ± 11.1 months. The mean JADAS10 score at baseline was 18.5 ± 5.9. By the third month, it had reduced to 8.6 ± 6.6 and by the sixth month to 5.7 ± 6. By the twelfth month, the JADAS10 score was 4.9 ± 6.7, and by the twenty-fourth month, it had worsened to 7.3 ± 7.8. ACR50 response was achieved in 79.6% of patients at 3 months, 67.1% at 6 months, 79.3% at twelfth months, 70.7% at the twenty-fourth month. During ETA treatment, 10 patients required hospitalization for serious infections.Conclusion: Etanercept is a safe and effective option for patients with JIA. However, variations in response between JIA subtypes highlight the need for individualized treatment strategies.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"855-862"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0